COVID-19 Pharmacotherapy: Drug Development, Repurposing of Drugs, and the Role of Pharmacogenomics

Authors

Rebecca Bock, Stern College for Women, Yeshiva University, New York, NY, USA.
Mariana Babayeva, Touro College of Pharmacy, New York, NY, USA.
Zvi G. Loewy, Touro College of Pharmacy, New York, NY, USA. Zvi.loewy@touro.edu.

Author Type(s)

Faculty

DOI

10.1007/978-1-0716-2573-6_8

Journal Title

Methods in Molecular Biology

First Page

187

Last Page

199

Document Type

Article

Publication Date

1-1-2022

Department

Pathology, Microbiology and Immunology

Abstract

The SARS-CoV-2 virus has been the subject of intense pharmacological research. Various pharmacotherapeutic approaches including antiviral and immunotherapy are being explored. A pandemic, however, cannot depend on the development of new drugs; the time required for conventional drug discovery and development is far too lengthy. As such, repurposing drugs is being used as a viable approach for identifying pharmacological agents for COVID-19 infections. Evaluation of repurposed drug candidates with pharmacogenomic analysis is being used to identify near-term pharmacological remedies for COVID-19.

Recommended Citation

Bock, R., Babayeva, M., & Loewy, Z. G. (2022). COVID-19 Pharmacotherapy: Drug Development, Repurposing of Drugs, and the Role of Pharmacogenomics. Methods in Molecular Biology, 2547, 187-199. https://doi.org/10.1007/978-1-0716-2573-6_8